{"commentary":{"count":18,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":10,"podcast":7,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06117774\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"DeLLphi-306","nct_id":"NCT06117774","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dellphi-306-nct06117774. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"DeLLphi-306","arms":[{"description":"Participants will receive tarlatamab on Cycle 1 Day 1, 8 and 15, and once every 2 weeks (Q2W) thereafter (cycle is 28 days).","label":"Tarlatamab","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo on Cycle 1 Day 1, 8 and 15, and Q2W thereafter (cycle is 28 days).","label":"Placebo","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-04-20","type":"ESTIMATED"},"conditions":["Limited Stage Small Cell Lung Cancer","Small Cell Lung Cancer"],"enrollment":{"count":404,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Tarlatamab","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-04-29","lead_sponsor":"Amgen","official_title":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-04-20","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PFS as Determined by BICR","timeFrame":"Up to approximately 6 years"},{"measure":"OS Over the Whole Trial","timeFrame":"Up to approximately 6 years"}],"references":[],"start_date":{"date":"2024-02-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)","url":"https://clinicaltrials.gov/study/NCT06117774"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dellphi-306-nct06117774"}